Zentek Ltd. (CVE:ZEN - Get Free Report)'s share price was up 10% on Friday . The company traded as high as C$1.60 and last traded at C$1.54. Approximately 81,255 shares traded hands during trading, an increase of 223% from the average daily volume of 25,159 shares. The stock had previously closed at C$1.40.
Zentek Stock Up 17.9 %
The firm has a market cap of C$171.68 million, a price-to-earnings ratio of -13.75 and a beta of 0.77. The company has a quick ratio of 7.59, a current ratio of 2.20 and a debt-to-equity ratio of 5.91. The firm has a fifty day moving average price of C$1.48 and a 200-day moving average price of C$1.28.
About Zentek
(
Get Free Report)
Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zentek, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentek wasn't on the list.
While Zentek currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
